Lynch syndrome (LS) is a genetic condition that is passed on between families (inherited). A syndrome is a group of signs and symptoms that occur together and point to a particular condition.
Most people who have Lynch syndrome are well and don’t know they have LS.
However, someone with LS is more at risk of developing certain types of cancer than other people of a similar age.
Check out our Men’s Health hub, full of helpful tips for healthy living and how to #SpotCancerEarly at: https://brnw.ch/21wKBEG
Also…
Many men with cancer in the family worry that they are at greater risk of getting it themselves. But this isn’t the case for most people. Cancer is a common disease among older people, so most families will include at least one person who has had cancer.
The strength of your family history depends on:
The more relatives who have had cancer, and the younger they were at diagnosis, the stronger your family history. You may have a strong family history if any of these situations apply to you:
Talk to your doctor who can help you find out if your family history of cancer is of concern. Your doctor may suggest that you visit regularly for screening. In this way, you can pick up problems early.
Your family history of cancer can change over time, so it is important to keep your doctor updated about any new cancers diagnosed in your family.
Family history may not make its way into the EHR at all. Barriers to obtaining a detailed and accurate family history have been well described, and improvements will require system-level strategies such as the genetic education of nongenetics providers, point-of-care risk assessments, interactive patient-facing software, and other solutions.
The EHR can play an important role in identifying candidates for LS screening and advancing the clinical care of patients with LS.
However, many limitations of the EHR need to be addressed and complementary approaches that incorporate input from all stakeholders are key to improving the lives of individuals with LS.
A new NHS testing programme for bowel cancer has been launched for people with Lynch Syndrome, following an initiative to increase genomic testing for the condition.
Around 10,000 people with Lynch syndrome will start receiving invitations to take part this year.
Dr Kevin Monahan, who led the NHS England Lynch syndrome transformation project, said: “Incorporating people with Lynch syndrome into the national colonoscopy screening programme is game-changing and will save many lives each year.
It will deliver prevention and early diagnosis of bowel cancer through timely and high-quality colonoscopy. Now diagnosis of this hereditary condition in England will be linked to lifelong patient-focused care.
“The most challenging part of dealing with Lynch syndrome for me is the uncertainty surrounding my son’s health. The fear of him possibly inheriting the mutation gives me anxiety, especially since he hasn’t been tested yet. If it were solely about me, I might have approached things differently — I may have postponed my prophylactic surgeries until after achieving menopause.”
“I didn’t have to face Lynch syndrome alone after realizing that support is always available. That support system, as well as staying ahead on check-ups and focusing on my wellbeing, guided my path after being diagnosed.”
The landscape of Lynch syndrome has significantly evolved over the past decade, with advancements in genetic testing, universal screening and predictive models improving early detection.
https://www.curetoday.com/view/what-i-wish-i-was-told-about-lynch-syndrome
https://pubmed.ncbi.nlm.nih.gov/38849509/
This study delves into the genomic landscape of EO-CRC, specifically focusing on pediatric (PED) and young adult (YA) patients, comparing them with adult (AD) CRC.
This study emphasizes the importance of comprehensive molecular investigations in EO-CRCs, which can potentially improve diagnostic accuracy, prognosis, and therapeutic decisions for these patients. Collaboration between the pediatric and adult oncology community is fundamental to improve oncological outcomes for this rare and challenging pediatric tumor.
This rise in colorectal cancer cases among young people has been well-documented in recent years. However, experts are still working to figure out what’s behind the trend.
The myth that someone can be too young to get cancer is just not true.
https://www.health.com/study-colorectal-cancer-rates-children-teens-8648696
The CanRisk tool, which operationalises the Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) is used by Clinical Geneticists, Genetic Counsellors, Breast Oncologists, Surgeons and Family History Nurses for breast cancer risk assessments both nationally and internationally. There are currently no guidelines with respect to the day-to-day clinical application of CanRisk and differing inputs to the model can result in different recommendations for practice.
Whilst consensus recommendations were achieved, the meeting highlighted some of the barriers limiting the use of CanRisk in clinical practice and identified areas that require further work and collaboration with relevant national bodies and policy makers to incorporate wider use of CanRisk into routine breast cancer risk assessments.
Professor Peter Elwood Honorary Professor, Cardiff University
There is a remarkable harmony between the effects of aspirin on the biological mechanisms of cancer metabolism and growth, and clinical evidence of reductions in cancer mortality and metastatic cancer spread.
Although aspirin increases the number of bleeds, the severity of bleeds attributable to aspirin is low, and the risk-benefit balance of aspirin appears to be favourable to aspirin.
Lynch Syndrome Ireland 